[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1% a",
    "url": "https://finnhub.io/api/news?id=70f41872ea9becf569137abb88fc6d2b93835e8df36c8c5c58bfe60b6c251977",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767992353,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 138052084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1% a",
      "url": "https://finnhub.io/api/news?id=70f41872ea9becf569137abb88fc6d2b93835e8df36c8c5c58bfe60b6c251977"
    }
  },
  {
    "ts": null,
    "headline": "Merck in Talks to Buy Revolution Medicines for Around $30 Billion",
    "summary": "Merck  is in talks to acquire  Revolution Medicines  in a deal that could value it at around $30 billion, according to people familiar with the matter.  A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail.  Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.",
    "url": "https://finnhub.io/api/news?id=372dfaefbc806ee2a44388550c6fdff2219dd6d6fd1129af613cd5e316feed18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767988680,
      "headline": "Merck in Talks to Buy Revolution Medicines for Around $30 Billion",
      "id": 138052272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck  is in talks to acquire  Revolution Medicines  in a deal that could value it at around $30 billion, according to people familiar with the matter.  A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail.  Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.",
      "url": "https://finnhub.io/api/news?id=372dfaefbc806ee2a44388550c6fdff2219dd6d6fd1129af613cd5e316feed18"
    }
  },
  {
    "ts": null,
    "headline": "Merck in Talks to Buy Revolution Medicines Per Financial Times Report",
    "summary": "Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.",
    "url": "https://finnhub.io/api/news?id=f05e59868fa739ee42389cc26db146320c9f472915c165f090611956c9b051c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767978180,
      "headline": "Merck in Talks to Buy Revolution Medicines Per Financial Times Report",
      "id": 138052275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.",
      "url": "https://finnhub.io/api/news?id=f05e59868fa739ee42389cc26db146320c9f472915c165f090611956c9b051c6"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals",
    "summary": "All three major US stock indexes were up in late-morning trading Friday, after the US Bureau of Labo",
    "url": "https://finnhub.io/api/news?id=3593b6c7a5222cc7ba26e8693ac84dfc4d4653b7c245b396d2b9fc98cfd44ac6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767977355,
      "headline": "Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals",
      "id": 138052388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Friday, after the US Bureau of Labo",
      "url": "https://finnhub.io/api/news?id=3593b6c7a5222cc7ba26e8693ac84dfc4d4653b7c245b396d2b9fc98cfd44ac6"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767975542,
      "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
      "id": 138052209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
      "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767973860,
      "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
      "id": 138052210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca"
    }
  },
  {
    "ts": null,
    "headline": "Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle",
    "summary": "RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=5392b16095136b8b34c52c3aea98faf5f617421865c392bbc1efc69e3891d891",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767969206,
      "headline": "Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle",
      "id": 138049147,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248270095/image_2248270095.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=5392b16095136b8b34c52c3aea98faf5f617421865c392bbc1efc69e3891d891"
    }
  },
  {
    "ts": null,
    "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
    "url": "https://finnhub.io/api/news?id=e0a75d6d7d92c1cc14e1481898b4cb2eaee811fcb3ac631a14336148bb1287ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968160,
      "headline": "BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?",
      "id": 138046679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure",
      "url": "https://finnhub.io/api/news?id=e0a75d6d7d92c1cc14e1481898b4cb2eaee811fcb3ac631a14336148bb1287ae"
    }
  },
  {
    "ts": null,
    "headline": "Betting on More Rate Cuts, Boomers Are Buying the 2026 Small Dogs of the Dow",
    "summary": "These five Dogs of the Dow may be the perfect play for 2026 for growth and income investors wary of volatility and a potential sell-off.",
    "url": "https://finnhub.io/api/news?id=5153fe31361010542b585bd61fe3cc7409629bbc2c9d0a722cddb21ee3aa5334",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767968012,
      "headline": "Betting on More Rate Cuts, Boomers Are Buying the 2026 Small Dogs of the Dow",
      "id": 138046670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These five Dogs of the Dow may be the perfect play for 2026 for growth and income investors wary of volatility and a potential sell-off.",
      "url": "https://finnhub.io/api/news?id=5153fe31361010542b585bd61fe3cc7409629bbc2c9d0a722cddb21ee3aa5334"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell",
    "summary": "US equity futures edged higher ahead of Friday's opening bell as traders digested the crucial monthl",
    "url": "https://finnhub.io/api/news?id=839be05acd1364258c97836a5251f401a5df5d32b857f1f1d2e5207a04a6e93c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767967664,
      "headline": "Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell",
      "id": 138046620,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity futures edged higher ahead of Friday's opening bell as traders digested the crucial monthl",
      "url": "https://finnhub.io/api/news?id=839be05acd1364258c97836a5251f401a5df5d32b857f1f1d2e5207a04a6e93c"
    }
  },
  {
    "ts": null,
    "headline": "Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck",
    "summary": "Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's \"Halftime Report\" to detail his latest portfolio moves.",
    "url": "https://finnhub.io/api/news?id=7a08e9c60fd20c64fb79a26728c74ad38f4f0c7bcd16b004a2c93026cb91a298",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767964047,
      "headline": "Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck",
      "id": 138057301,
      "image": "https://image.cnbcfm.com/api/v1/image/108250621-17679799131767979906-43412985450-1080pnbcnews.jpg?v=1767979913&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's \"Halftime Report\" to detail his latest portfolio moves.",
      "url": "https://finnhub.io/api/news?id=7a08e9c60fd20c64fb79a26728c74ad38f4f0c7bcd16b004a2c93026cb91a298"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
    "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
    "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963421,
      "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
      "id": 138057238,
      "image": "https://image.cnbcfm.com/api/v1/image/108222520-17624504352025-11-06t173326z_182594845_rc24rhaozaeo_rtrmadp_0_usa-trump.jpeg?v=1767995336&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
      "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307"
    }
  },
  {
    "ts": null,
    "headline": "Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.",
    "summary": "Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.",
    "url": "https://finnhub.io/api/news?id=71454e56cb8644c903271ec6f79902ea0eda92156b6fd9c59654511c1c549385",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767956040,
      "headline": "Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.",
      "id": 138045485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.",
      "url": "https://finnhub.io/api/news?id=71454e56cb8644c903271ec6f79902ea0eda92156b6fd9c59654511c1c549385"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Strikes Deal With White House to Lower Drug Prices",
    "summary": "Johnson & Johnson  has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.  “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday.  Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”",
    "url": "https://finnhub.io/api/news?id=e7f42c4b24d63a7e1512cb192d4418f2b5964d578781bfe65390f3d46123700e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767953400,
      "headline": "Johnson & Johnson Strikes Deal With White House to Lower Drug Prices",
      "id": 138045478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Johnson & Johnson  has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.  “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday.  Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”",
      "url": "https://finnhub.io/api/news?id=e7f42c4b24d63a7e1512cb192d4418f2b5964d578781bfe65390f3d46123700e"
    }
  },
  {
    "ts": null,
    "headline": "A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year",
    "summary": "Europe's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.",
    "url": "https://finnhub.io/api/news?id=cc51c9aede062004e513ac24dc4422785f4f1d88fe05c91bc25359ab1c9950e1",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767941677,
      "headline": "A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year",
      "id": 138047616,
      "image": "https://image.cnbcfm.com/api/v1/image/108249930-1767883114856-gettyimages-1457781967-_x3m2814.jpeg?v=1767883140&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Europe's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.",
      "url": "https://finnhub.io/api/news?id=cc51c9aede062004e513ac24dc4422785f4f1d88fe05c91bc25359ab1c9950e1"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Jobs Data, Trump Tariffs Ruling Loom After Small Caps Lead",
    "summary": "Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.",
    "url": "https://finnhub.io/api/news?id=4ddf1005a42686e66ff4d4b13a65f6cb85e512d0035656395f7a3bcee5e598f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767929114,
      "headline": "Dow Jones Futures: Jobs Data, Trump Tariffs Ruling Loom After Small Caps Lead",
      "id": 138042898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.",
      "url": "https://finnhub.io/api/news?id=4ddf1005a42686e66ff4d4b13a65f6cb85e512d0035656395f7a3bcee5e598f0"
    }
  },
  {
    "ts": null,
    "headline": "Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn",
    "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...",
    "url": "https://finnhub.io/api/news?id=2fdfa40169b39d2f5d234447f960289a1c6ca3bf48d7d286265b50e05ae07af7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767919891,
      "headline": "Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn",
      "id": 138043171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...",
      "url": "https://finnhub.io/api/news?id=2fdfa40169b39d2f5d234447f960289a1c6ca3bf48d7d286265b50e05ae07af7"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Upgrades Merck (MRK)",
    "summary": "Wolfe Research Upgrades Merck (MRK)",
    "url": "https://finnhub.io/api/news?id=dffeb7f0db8280f73005318dd5b894455cf5657a0c1302b50d141827cb5fed56",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767917066,
      "headline": "Wolfe Research Upgrades Merck (MRK)",
      "id": 138040913,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=dffeb7f0db8280f73005318dd5b894455cf5657a0c1302b50d141827cb5fed56"
    }
  }
]